Today, Yahoo! (NASDAQ: YHOO) will have its annual shareholders meeting and CEO Terry Semel's compensation will likely be an issue.
Yahoo!'s glory has been getting trounced on lately, even as the company apparently sees good results from its recent launch of Project Panama. Project Panama, the company's new advertising system, intended to compete with Google (NASDAQ: GOOG), is still not getting any kind of good press. Meanwhile, Google expands its leading position and the internet media darling keeps anything and everything Yahoo! out of the limelight. That is, until it comes to the compensation of Yahoo!'s CEO, Terry Semel. He's getting paid way too handsomely for what many consider lackluster performance. And, it's only going to get worse before it gets any better.
YHOO shares have languished around the $30 level for some time now, and things are just not falling Yahoo!'s way, especially when it comes to competing with Google and a newly-resurgent Microsoft as well. Add to that CEO Terry Semel's brash claims three years ago that Yahoo! would remain the internet's brightest star along with Semel's recent pay and it's not hard to see why the CEO is in the hot seat.
Will 2007 see the end of Semel as Yahoo!'s illustrious leader? In all estimations, it will. Yahoo! has lost its shine this year as Google has completely eclipsed it, and the company's "wandering" status -- even as it continues to make a decent pile of cash each quarter -- is not sitting well with shareholders who see Yahoo! as a laggard while other companies race past it. If Semel does go this year, there will be two responsible people: Google co-founders Larry Page and Sergey Brin.
Last updated: February 10, 2012: 01:19 AM
Hot Stocks
DailyFinance Headlines
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
Benzinga Headlines
TheFlyOnTheWall.com Headlines
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

